Ignite Creation Date:
2025-12-24 @ 5:38 PM
Ignite Modification Date:
2026-02-03 @ 7:56 PM
Study NCT ID:
NCT07082868
Status:
RECRUITING
Last Update Posted:
2025-10-20
First Post:
2025-07-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Primary Central Nervous System Lymphoma (PCNSL) | View |
| None | Primary Central Nervous System Lymphoma | View |
| None | Relapsed Primary Central Nervous System Lymphoma | View |
| None | Refractory Primary Central Nervous System Lymphoma | View |
| None | Central Nervous System Lymphoma | View |
| None | Secondary Central Nervous System Lymphoma | View |
| None | Secondary Central Nervous System Lymphoma (SCNSL) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Primary Central Nervous System Lymphoma | View |
| None | PCNSL | View |
| None | Relapsed Primary Central Nervous Lymphoma | View |
| None | Refractory Primary Central Nervous Lymphoma | View |
| None | Central Nervous System Lymphoma | View |
| None | Secondary Central Nervous System Lymphoma | View |
| None | SCNSL | View |
| None | epcoritamab | View |
| None | ibrutinib | View |
| None | 25-032 | View |
| None | Memorial Sloan Kettering Cancer Center | View |